share_log

In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics

Benzinga ·  Nov 14 00:00

During the last three months, 11 analysts shared their evaluations of Viridian Therapeutics (NASDAQ:VRDN), revealing diverse outlooks from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings83000
Last 30D10000
1M Ago10000
2M Ago11000
3M Ago52000

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $40.18, along with a high estimate of $61.00 and a low estimate of $27.00. This current average reflects an increase of 9.39% from the previous average price target of $36.73.

bigjpg

Interpreting Analyst Ratings: A Closer Look

The standing of Viridian Therapeutics among...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment